Pacira BioSciences trades below the $1 billion minimum investable universe threshold at $890 million market cap, carries a perfect 9/9 Piotroski F-Score with exceptional free cash flow conversion, but faces 24% short interest, a put/call ratio of 7.00, and capitulation-risk RSI near 30 — making this a sub-threshold speculative situation rather than a standard investment.
Thesis pillars
- Below Threshold Market Cap Flag↓Deteriorating
- Perfect Piotroski Fcf Quality→Stable
- Elevated Put Call Short Interest Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pacira BioSciences, Inc. (PCRX) Stock Analysis
Catalyst-Driven edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $25.88 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
Pacira BioSciences is a biopharmaceutical company commercializing three non-opioid pain therapies: EXPAREL, a long-acting local analgesic for postsurgical pain that accounted for 79% of 2025 revenue; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee... Read more
Sell if holding. Analyst target reached at $25.88 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Pacira BioSciences, Inc.
About Pacira BioSciences, Inc.
Pacira BioSciences generated $575.1 million in net EXPAREL sales in 2025, up from $549.0 million in 2024, representing 79% of the company's total revenue, while ZILRETTA contributed $116.6 million (16% of revenue) and iovera° added $24.2 million. Under its January 2025 '5x30' strategic plan, Pacira reached 2.5 million patients treated in 2025 and is targeting more than 3 million patients annually, double-digit revenue growth, and a five-percentage-point gross margin improvement by 2030.
Pacira earns revenue from direct U.S. commercial sales of EXPAREL (bupivacaine liposome injectable suspension) across orthopedic, abdominal and colorectal, women's health, cardiothoracic, and pediatric surgical markets, plus ZILRETTA, a physician-administered, buy-and-bill corticosteroid injection for osteoarthritis knee pain now co-promoted with J&J MedTech under a July 2025 agreement. The company relies on third-party manufacturers, including Thermo Fisher and Amphenol, and stores finished goods across three warehouses maintained by two service providers, with EXPAREL requiring cold-chain distribution to preserve product integrity. Pacira has grown its portfolio through acquisitions, including Flexion Therapeutics in November 2021 and GQ Bio Therapeutics in February 2025, and continues developing PCRX-201, a Phase 2 gene therapy candidate for knee osteoarthritis from its high-capacity adenovirus vector platform.
Show full overview
Pacira's own risk factors state that the company's success depends primarily on its ability to commercialize EXPAREL and ZILRETTA, which together accounted for 95% of 2025 revenue (79% and 16%, respectively), leaving results highly sensitive to formulary approvals, third-party reimbursement rates, and the NOPAIN Act's new separate Medicare reimbursement for non-opioids like EXPAREL that took effect in January 2025. The company also faces active patent litigation against WhiteOak and Qilu over EXPAREL and ZILRETTA intellectual property, an outcome that could affect the exclusivity underpinning both products' pricing power.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Pacira BioSciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — Pacira BioSciences, Inc.
Latest news
- NEWS PCRX (Pacira BioSciences Inc.) reports steep Q4 2025 EPS miss while shares rise 3.6 percent on favorable investor sentim — Cổng thông tin điện tử tỉnh Tây Ninh negative
- NEWS Pacira Biosciences Inc Live Share Prices and Trades. PCRX.US Live Streaming Share Prices. - London South East — London South East neutral
- NEWS Pacira Biosciences Live Share Prices and Trades. PCRX.US Live Streaming Share Prices. - London South East — London South East neutral
- NEWS Do options traders know something about Pacira BioSciences stock we don't? - MSN — MSN neutral
- NEWS Is It Too Late to Buy Pacira BioSciences Inc (PCRX) After 4.3% R - GuruFocus — GuruFocus neutral
Generated 2026-07-26T09:27:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $25.88 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.22. Score 5.2/10, moderate confidence.
Take-profit target: $26.13 (-0.3% upside). Prior stop was $24.22. Stop-loss: $24.22.
Analyst target reached - limited upside remaining; Weak growth; Elevated risk factors.
Pacira BioSciences, Inc. trades at a P/E of 199.1 (forward 7.1). TrendMatrix value score: 6.8/10. Verdict: Sell.
12 analysts cover PCRX with a consensus score of 3.8/5. Average price target: $30.
What does Pacira BioSciences, Inc. do?Pacira BioSciences is a biopharmaceutical company commercializing three non-opioid pain therapies: EXPAREL, a...
Pacira BioSciences is a biopharmaceutical company commercializing three non-opioid pain therapies: EXPAREL, a long-acting local analgesic for postsurgical pain that accounted for 79% of 2025 revenue; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain (16% of revenue); and iovera°, a cryoanalgesia device. The company is also advancing PCRX-201, a Phase 2 gene therapy for knee osteoarthritis from its proprietary high-capacity adenovirus vector platform. Under its '5x30' strategic plan launched in January 2025, Pacira aims to reach more than 3 million patients ann